Market Views – Page 31 – media

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 689
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
Genetic testing startup Prenetics raised $40M in Series B round led by Alibaba’s Hong Kong fund and Beyond Ventures

Genetic testing startup Prenetics has raised $40 million in a Series B funding round led by Hong Kong-based venture capital fund Beyond Ventures and the Alibaba Hong Kong Entrepreneurs Fund.
- Source: Mastsea
- 567
- October 19, 2017
Artificial Intelligence Market Views Series
U.S. pressing India to avoid capping medical device prices, allow withdrawals

Indian Prime Minister Narendra Modi’s government has in recent months slashed prices of medical devices such as knee implants and heart stents by up to 75 percent to make them more affordable.
- Source: reuters
- 442
- October 19, 2017
Market Views medical device
A Significant Global Problem

A study of the global prevalence of fetal alcohol spectrum disorder (FASD) estimates that it affects as many as 8 out of 10,000 children, highlighting the need to improve public education about the potential harm of drinking alcohol during pregnancy.
- Source: medicalnewsbulletin
- 525
- October 18, 2017
alcohol FASD fetus Market Views
InflaRx announces a $ 55M Series D financing and investment round

InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced a $ 55M Series D financing and investment round.
- Source: inflarx.de
- 594
- October 17, 2017
Market Views Series therapeutics
Warp Drive Bio Forms Strategic Collaboration to Advance Novel Classes of Antibiotics

Warp Drive Bio, Inc., a drug discovery company developing therapeutics that exploit the molecules and mechanisms of nature, announced today that it has formed a strategic collaboration with Roche to discover and develop multiple novel classes of antibiotics. The serious global health threat of multi-drug-resistant bacterial infections has created an urgent need for new antibiotics with novel structures and mechanisms of action.
- Source: Businesswire
- 435
- October 17, 2017
antibiotics infections Market Views
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 558
- October 16, 2017
Market Views NIH PACT
Merck buys into KalVista and its DME candidate

Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million. Under the deal, Merck, which is known as MSD outside of the US and Canada, is paying KalVista $37 million upfront and taking a 9.9 percent stake in the firm in return for access to its experimental diabetic macular oedema drug KVD001.
- Source: Pharmatime
- 599
- October 12, 2017
diabetic macular Market Views oedema
Ebola vaccine tests hailed a success

The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
- Source: medicalxpress
- 1,181
- October 11, 2017
Ebola Market Views vaccine
Magenta Medical, Developer of Novel Heart Failure Therapies, Secures $15 Million in Series B Financing

Magenta Medical was founded in October, 2012 by Prof. Ehud Schwammenthal and Mr. Yosi Tuval, Magenta Medical is developing novel therapeutic approaches to the management and treatment of Acute Heart Failure.
- Source: Infomeddnews
- 448
- October 11, 2017
Acute Heart Failure Market Views therapeutic

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.